New Leaf Venture Partners

Founded 2005
Founders James Niedel Jeani Delagardelle Philippe Chambon Vijay Lathi

Overview

Unlock datapoints

Portfolio analytics

Team

Investments

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.
Total investments 156
Average round size
info
The average size of a deal this fund participated in
$34M
Portfolio companies 81
Rounds per year 9.75
Lead investments 22
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.48
Exits 43
Key employees 2
Stages of investment
Early Stage Venture
Late Stage Venture
Private Equity

Areas of investment

  • Health Care
  • Biotechnology
  • Medical
  • Medical Device
  • Health Diagnostics
Summary

New Leaf Venture Partners appeared to be the VC, which was created in 2005. The fund was located in North America if to be more exact in United States. The main department of described VC is located in the New York.

The high activity for fund was in 2012. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 6 percentage points more often commits exit comparing to other organizations. When the investment is from New Leaf Venture Partners the average startup value is more than 1 billion dollars. Comparing to the other companies, this New Leaf Venture Partners performs on 3 percentage points less the average number of lead investments. The top amount of exits for fund were in 2018. Deals in the range of 10 - 50 millions dollars are the general things for fund. The fund is constantly included in 7-12 deals per year.

The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the New Leaf Venture Partners, startups are often financed by Spray Venture Partners, InterWest Partners, Versant Ventures. The meaningful sponsors for the fund in investment in the same round are Sofinnova Investments, Aberdare Ventures, Clarus Ventures. In the next rounds fund is usually obtained by SV Health Investors, Aberdare Ventures, Three Arch Partners.

This organization was formed by James Niedel, Jeani Delagardelle, Philippe Chambon, Ronald M. Hunt, Vijay Lathi. The overall number of key employees were 2.

Among the most successful fund investment fields, there are Genetics, Health Diagnostics. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. Among the various public portfolio startups of the fund, we may underline Synageva BioPharma, Intarcia Therapeutics, Relypsa The fund has no exact preference in some founders of portfolio startups. If startup sums 5+ of the founder, the chance for it to be financed is low. Besides, a startup requires to be at the age of 4-5 years to receive the investment from the fund.

Read more

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Asimily

Cyber Security
Data Visualization
Hospital
Software
$10M02 Nov 2021 Sunnyvale, California, United States

Cleerly

Apps
Artificial Intelligence
Education
Health Care
Information Technology
Medical
$43M21 Jun 2021 New York, New York, United States

Akili Interactive Labs

Biotechnology
Health Care
Medical
Medical Device
Neuroscience
Therapeutics
$110M26 May 2021 Boston, Massachusetts, United States

BrightInsight

Biopharma
Health Care
Medical
Software
$101M30 Mar 2021 San Jose, California, United States

TigerConnect

Compliance
Enterprise
Health Care
Messaging
mHealth
Privacy
Text Analytics
$11M08 Oct 2020 Santa Monica, California, United States

ReViral

Biotechnology
Health Care
Medical
Therapeutics
$44M25 Aug 2020 England

Saniona

Biotechnology
$65M10 Aug 2020 Denmark, Capital Region of Denmark, Denmark

Biotechnology
Health Care
Life Science
Medical Device
Nanotechnology
$46M15 Jul 2020 Cambridge, Massachusetts, United States

BrightInsight

Biopharma
Health Care
Medical
Software
$40M23 Jun 2020 San Jose, California, United States
News
DiCE Molecules Announces $60 Million Series C-1 Financing

– DiCE Molecules, a biopharmaceutical company leveraging its proprietary DNA-encoded library platform to discover and develop next-generation therapeutics in immunology and other therapeutic areas, announced the completion of its $60 million Series C-1 financing.
– The financing was led by RA Capital Management and Sands Capital, with participation from new investors Janus Henderson Investors, Deep Track Capital and Logos Capital.
– Existing investors Northpond Ventures, Eventide Asset Management, Driehaus Capital Management, Soleus Capital, New Leaf Venture Partners, Osage University Partners and Asymmetry Capital Management also participated in the round.
– With the closing of this Series C-1 financing round, the Company has raised approximately $200 million to date.

Cleerly Raises $43M in Series B Funding

– Cleerly, a NYC-based company creating a new standard of care for heart disease, launched with $43m in Series B funding.
– The round was led by Vensana Capital with participation from LRVHealth, New Leaf Venture Partners, DigiTx Partners, the American College of Cardiology, Cigna Ventures, and existing investors.
– The company intends to use the funds to scale its commercial reach, expand operational capabilities and strategic partnerships, and continue to grow its focus on research and development.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent New Leaf Venture Partners?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!

Wait!
You can raise money with us faster

Get matched with relevant funds

Find decision makers data

Connect with investors by email

Remind me later
...and save more than 200 hours*
*-Our recommendation and outreach system saves up to 200 hours of founder time on fundraising for seed and series A+ startups
We use LinkedIn only to verify your account. We don't import or message your contacts, nor post on your behalf.
By creating an account, you agree to our Terms of Service and Privacy Policy.
Crunchbase icon

Content report

The following text will be sent to our editors: